According to the report, the Asia Pacific Clinical Data Analytics Market Size was valued at USD 1.15 billion in 2021. Furthermore, it is expected to grow at a CAGR of 48.92%, to reach USD 8.40 billion by 2026 during the forecast period 2021 to 2026.
In the healthcare industry, clinical data analytics plays a critical role in curing and predicting disease, increasing care quality, and preventing unnecessary deaths caused by chronic disease neglect.
In recent years, the general public has been more concerned with health management; it is one of the primary driving forces in the clinical data analytics industry. Furthermore, favorable government regulations, cost savings, and increased opportunities to provide people with high-quality services also contribute to the market's growth.
However, with the rise of the big data business in healthcare, the market has grown significantly. Big data has been attributed to improving healthcare results, saving lives, and doing it for a low cost.
Further, clinical data analytics is one of the areas that has seen a lot of growth in the following years; this is due to the advancement of science and technology and IoT, AI, and other interactive applications. In addition, the demand for clinical data analytics was sparked by the need for tailored healthcare and frequent health and fitness maintenance.
The demand for clinical data analytics was further boosted by government legislation requiring data repositories and data fiduciaries for health monitoring.
End-user market fragmentation, software privacy difficulties, and security issues are some of the challenges and restrictions facing the clinical data analytics market. In addition, lockdowns imposed to stop the spread of the COVID-19 pandemic have thrown the clinical data analytics sector into turmoil. Aside from the unexpected loss in revenue, several firms are projected to confront a slew of new issues due to the epidemic.
This research report on the Asia Pacific Clinical Data Analytics Market has been segmented and sub-segmented into categories.
By Deployment Model:
By End User:
By Country:
In the Asia-Pacific region, the clinical data analytics industry is quickly expanding. The market growth is driven by the increase in clinical trials and an aging population in this region. Furthermore, regional market growth is supported by the increased demand from patient groups adopting healthcare data analytics to manage big data.
The key markets in the region with considerable unmet needs are China and India. Thus, the Asia Pacific clinical data analytics market will likely generate a sizable revenue stream over the forecast period.
The Asia-Pacific economy is expanding rapidly. Countries such as India, China, Japan, and Australia are propelling the region's economic development. The primary source of concern in this region is providing adequate healthcare for the region's rapidly rising population. With the opening of new hospitals and pharmacies in this area, there will be much patient data on the market.
China's clinical data analytics market has become a hotspot for clinical data analytics in healthcare due to an expanding patient pool, constantly increasing drug development costs and schedules, and a growing opportunity in the pharmaceutical business. Multinational pharmaceutical companies, contract research organizations (CRO), academic institutions, and service providers have taken advantage of recent regulatory changes in China to establish their presence in the drug manufacturing industry, paving the way for the region's clinical data analytics to grow.
On the other hand, the Indian clinical data analytics market is anticipated to record a promising share in the coming years. Improving healthcare infrastructure, supportive government policies, and the development of pharmaceutical companies in the country contribute to market growth.
Top Companies leading the Asia Pacific Clinical Data Analytics Market Profiled in the Report are IBM, CareEvolution, Intersystems, Explorys, Cerner, Caradigm, Truven Health Analytics, Wellcentive, McKesson, Athenahealth.,
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Deployment Model
5.1.1 Introduction
5.1.2 Cloud
5.1.3 On-Premise
5.1.4 Y-o-Y Growth Analysis, By Deployment Model
5.1.5 Market Attractiveness Analysis, By Deployment Model
5.1.6 Market Share Analysis, By Deployment Model
5.2 Services
5.2.1 Introduction
5.2.2 Consulting
5.2.3 Maintenance
5.2.4 Y-o-Y Growth Analysis, By Services
5.2.5 Market Attractiveness Analysis, By Services
5.2.6 Market Share Analysis, By Services
5.3 End-User Sector
5.3.1 Introduction
5.3.2 Pharmaceuticals
5.3.3 Healthcare Providers
5.3.4 Biotechnology
5.3.5 Academia
5.3.6 Y-o-Y Growth Analysis, By End-User Sector
5.3.7 Market Attractiveness Analysis, By End User Sector
5.3.8 Market Share Analysis, By End-User Sector
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Deployment Model
6.1.3.3 By Services
6.1.3.4 By End User Sector
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Deployment Model
6.1.4.3 By Services
6.1.4.4 By End Use Sector
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Deployment Model
6.1.5.3 By Services
6.1.5.4 By End Use Sector
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
6.7 Rest of Asia Pacific
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 IBM
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 CareEvolution
8.3 Cardigm
8.4 Explorys
8.5 Cerner
8.6 Intersystems
8.7 Athenahealth
8.8 Truven Health Analytics
8.9 Wellcentive
8.10 McKesson
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
